SUO 2017: The REASSURE ME Trial

Washington, DC (UroToday.com) While active surveillance (AS) for the management of low risk prostate cancer is becoming an increasingly adopted treatment paradigm, many men and their partners can face a host of psychosocial stressors related to this approach. As such, Dr. Herrel and colleagues presented their trial design for the REASSURE ME trial, supporting emotion regulation, positive health behaviors, and surveillance adherence for men with prostate cancer on active surveillance. Psychosocial stressors can negatively affect short and long term psychosocial adjustment and quality of life and contribute to withdrawal from AS prematurely to seek definitive therapies such as surgery. The objective of this trial is to use a multi-site approach to examine the efficacy of mindfulness training compared with a time/attention−matched health promotion control among a large sample of men on AS and their spouses. 

SUO 2017: Surgical And Imaging Findings Of Neoadjuvant Enzalutamide And Androgen Deprivation Therapy For High Risk Prostate Cancer: An Initial Case Study For An Ongoing Clinical Trial

Washington, DC (UroToday.com) Introduction: Neoadjuvant androgen deprivation therapy (ADT) for high-risk prostate cancer (PCa) has been shown to decrease the risk of positive surgical margins, but promotes no improvements in biochemical recurrence (BCR) or survival.

SUO 2017: Longitudinal Assessment Of Health-related Quality Of Life And Decisional Regret In Men With Localized Prostate Cancer

Washington, DC (UroToday.com) Introduction: Patients with clinically localized prostate cancer (PCa) are faced with the challenging process of selecting an optimal therapy for their disease. Treatment choice can impact health-related quality of life (HRQOL) specifically urinary, sexual, and bowel functioning that can further lead to the decisional regret.

SUO 2017: Mutations And Gene Expression Differences Between African Americans And Non-African Americans With Urothelial Cell Carcinoma

Washington, DC (UroToday.com) While race has been established as a strong predictor in many malignancies, including prostate cancer, there is little evidence in bladder cancer. While African American’s with bladder cancer have been shown to have worse disease specific and overall survival, several factors such as socioeconomic status, access to care, and stage at presentation have been proposed as confounding variables; it remains unclear why this difference exists. However, part of the problem lies in the lack of large studies assessing non-Caucasian patients. Hence, any large series of non-Caucasian patients carries significant value.

SUO 2017: Oncologic Outcomes Comparing Open and Robot-Assisted Laparoscopic Radical Cystectomy for Bladder Cancer

Washington, DC (UroToday.com) Dr. Marzouk and colleagues from Memorial Sloan Kettering Cancer Center reported oncological outcomes from their randomized control trial (RCT) comparing open (ORC) to robotic radical cystectomy (RARC). The authors previously reported the primary endpoints evaluating perioperative outcomes for ORC vs RARC1 demonstrating no advantage for robotic-assisted techniques over standard open surgery with regards to 90-day complication rates, length of hospital stay, and 3- and 6-month quality of life outcomes. The objective of this study was to report secondary endpoints of cancer specific outcomes from this prospective, randomized trial comparing RARC vs ORC. 

SUO 2017: Primary Focal Cryoablation For Low-, Intermediate- And High-risk Prostate Cancer

Washington, DC (UroToday.com) Introduction: In this study the authors aimed to evaluate the oncologic and functional outcomes of primary focal cryoablation (PFC) for low-, intermediate- and high-risk prostate cancer (PCa) patients.

SUO 2017: Anterior Prostate Lesions and Prostate Cancer Diagnosed in African American Men

Washington, DC (UroToday.com) African American (AA) men often present with higher risk prostate cancer than non-AA men. It is believed that anterior prostate lesions may be greater and more aggressive in AA men leading to evasion of detection, and studies of pathologic specimens have supported this notion [1]. Dr. Gupta and colleagues presented their institutions experience with anterior prostate cancer lesions in AA-men. The objective of this study was to compare the rates and grade of anterior prostate lesions in AA and non-AA men without an existing diagnosis of prostate cancer.
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe